LTA: Lymphotoxin-alpha
Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on LTA, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Pateclizumab | Phase 2 | Roche | Antibody | InhibitorTNF-beta inhibitor | 0 |
- Psoriatic arthritis0.38
- Neurodegenerative disease0.37
- Rheumatoid arthritis0.14
- Colorectal carcinoma0.11
- Neoplasm0.10
- Experimental autoimmune encephalomyelitis0.10
- Systemic lupus erythematosus0.09
- BENTA disease0.09
- Hyper-IgM syndrome type 30.08
- Nephritis0.08
- Graft versus host disease0.08
- Vitiligo0.08
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2059, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P01374, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets